Retrieved on:
Saturday, January 27, 2024
If you are an Eagle shareholder, click here to learn more about your rights and options .
Key Points:
- If you are an Eagle shareholder, click here to learn more about your rights and options .
- If you are a Freeline shareholder, click here to learn more about your rights and options .
- Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Retrieved on:
Wednesday, November 29, 2023
If you are a P&F shareholder, click here to learn more about your rights and options .
Key Points:
- If you are a P&F shareholder, click here to learn more about your rights and options .
- If you are a Freeline shareholder, click here to learn more about your rights and options .
- Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Retrieved on:
Thursday, November 23, 2023
If you are a Spirit Realty shareholder, click here to learn more about your rights and options .
Key Points:
- If you are a Spirit Realty shareholder, click here to learn more about your rights and options .
- If you are a Patriot shareholder, click here to learn more about your rights and options .
- Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Retrieved on:
Wednesday, November 22, 2023
Empire,
Amphenol,
Sale,
Monteverde,
RPT Realty,
Therapy,
Kimco Realty,
RPT,
CSTR,
PCTI,
Old National Bank,
Security (finance) Under the terms of the agreement, FRLN shareholders will receive $6.50 in cash per share they own.
Key Points:
- Under the terms of the agreement, FRLN shareholders will receive $6.50 in cash per share they own.
- Under the terms of the agreement, CSTR shareholders will receive 1.155 shares of Old National per share they own.
- RPT Realty (NYSE: RPT ), relating to its proposed merger with Kimco Realty.
- Under the terms of the agreement, RPT shareholders are expected to receive 0.6049 shares of Kimco per share they own.
Retrieved on:
Tuesday, November 28, 2023
and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Freeline Therapeutics Holdings plc (NasdaqCM: FRLN) to Syncona Ltd.
Key Points:
- and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Freeline Therapeutics Holdings plc (NasdaqCM: FRLN) to Syncona Ltd.
- Under the terms of the proposed transaction, shareholders of Freeline will receive $6.50 for each American Depositary Share (ADS) of Freeline that they own.
- KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
- To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .
Retrieved on:
Wednesday, November 22, 2023
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Freeline Therapeutics Holdings plc (NASDAQ: FRLN) to Syncona Ltd. for $6.50 per American Depositary Share is fair to Freeline shareholders.
Key Points:
- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Freeline Therapeutics Holdings plc (NASDAQ: FRLN) to Syncona Ltd. for $6.50 per American Depositary Share is fair to Freeline shareholders.
- On behalf of Freeline shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
- Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Congress,
Cell,
Glucocerebrosidase,
Gene,
Safety,
CEST,
Gaucher's disease,
AAV,
ESGCT,
European Society of Gene and Cell Therapy,
Patient,
Pharmaceutical industry The oral presentation will include data on safety, tolerability, GCase enzyme activity, substrate, and hemoglobin and platelet levels from the first two patients treated with FLT201.
Key Points:
- The oral presentation will include data on safety, tolerability, GCase enzyme activity, substrate, and hemoglobin and platelet levels from the first two patients treated with FLT201.
- Details of the oral presentation are below:
Date and Time: Wednesday, October 25 from 14:30-16:30 CEST (8:30-10:30 a.m.
- ET)
Additional details on the meeting can be found at the ESGCT 30th Annual Congress website .
- The presentation materials will be available on the Investors section of Freeline’s website following presentation at the ESGCT Congress.
Retrieved on:
Wednesday, October 4, 2023
Gaucher's disease,
Half-life,
First grade,
Cell,
Bone pain,
AAV,
Plasma,
Patient,
White blood cell,
ALT,
Liver,
Enzyme replacement therapy,
Therapy,
AST,
Study,
White,
Safety,
Disease,
Pharmaceutical industry,
Vaccine,
Medical imaging,
Glucocerebrosidase LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Gaucher disease is a debilitating genetic disorder in which a deficiency of the GCase enzyme leads to a buildup of harmful substrates, causing symptoms including enlarged spleen and liver, low blood counts, bone pain and reduced lung function. In addition to demonstrating a favorable safety and tolerability profile, data from the first two patients in GALILEO-1 show that a single infusion of FLT201 led to several hundred-fold increases in GCase activity in plasma and normalization of GCase activity in leukocytes.
Key Points:
- ET
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease.
- "These initial clinical data are very compelling,” said Pilar Giraldo, M.D., Ph.D., hematologist at the Spanish Foundation for the Study and Therapy of Gaucher Disease, Quirónsalud Hospital – Zaragoza, and an investigator in the GALILEO-1 trial.
- “While existing therapies have had a significant impact on the disease, many patients continue to experience symptoms and current therapies come with a heavy lifelong treatment burden.
- ET today to discuss these initial clinical data for FLT201 in Gaucher disease.
Gaucher's disease,
GBA1,
ADS,
CMC,
G&A,
AAV,
Sale,
Patient,
Administration,
Research and development,
R,
Research,
Glucocerebrosidase,
Safety,
Disease,
Pharmaceutical industry,
Gaucher,
Daimler Freeline LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the second quarter of 2023 and provided a business update.
Key Points:
- ET today
LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the second quarter of 2023 and provided a business update.
- Today, Freeline announced the dosing of the second patient in its GALILEO-1 trial of FLT201, marking the completion of dosing in the first cohort.
- Cash Position: As of June 30, 2023, unrestricted cash and cash equivalents were $38.8 million, compared to $55.4 million as of March 31, 2023.
- Freeline expects its current level of cash and cash equivalents will enable the company to fund its planned operations into the second quarter of 2024.
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m.
Key Points:
- LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m.
- ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update.
- While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start.
- A live webcast of the call will also be available on the Investors section of Freeline’s website at www.freeline.life .
